Back to today’s briefing

Story perspectives

FDA Designates Elironrasib Breakthrough Therapy for Lung Cancer

7/25/2025

33 7

Summary

Story summary

The FDA has awarded breakthrough therapy designation to elironrasib (RMC-6291) for adult patients battling KRAS G12C-mutated non-small cell lung cancer (NSCLC) who haven't tried a KRAS G12C inhibitor before. This pivotal decision stems from encouraging findings in the phase 1 RMC-6291-001 trial, underscoring the urgent demand for innovative treatments in RAS-driven cancers.

1 of 1

Story summary

The FDA has awarded breakthrough therapy designation to elironrasib (RMC-6291) for adult patients battling KRAS G12C-mutated non-small cell lung cancer (NSCLC) who haven't tried a KRAS G12C inhibitor before. This pivotal decision stems from encouraging findings in the phase 1 RMC-6291-001 trial, underscoring the urgent demand for innovative treatments in RAS-driven cancers.